1-9 of 9
Laura Q.M. Chow
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non–Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges

Laura Q.M. Chow, Fabrice Barlesi, Erin M. Bertino, Martin J. van den Bent, Heather A. Wakelee, Patrick Y. Wen, Chao-Hua Chiu, Sergey Orlov, Rita Chiari, Margarita Majem, Mark McKeage, Chong-Jen Yu, Pilar Garrido, Felipe K. Hurtado, Pilar Cazorla Arratia, Yuanbo Song, Fabrice Branle, Michael Shi, Dong-Wan Kim
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (12): 2506–2516.
https://doi.org/10.1158/1078-0432.CCR-21-1838
Published: 13 June 2022
View article titled, ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with <em>ALK</em>-Positive Non–Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges
Open the PDF for ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with <em>ALK</em>-Positive Non–Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges in another window
Includes: Supplementary data
Journal Articles

A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non–small Cell Lung Cancer

Edward B. Garon, Alexander I. Spira, Melissa Johnson, Lyudmila Bazhenova, Joseph Leach, Amy L. Cummings, Albert Candia, Robert L. Coffman, Mary J. Janatpour, Robert Janssen, Erick Gamelin, Laura Q.M. Chow
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (16): 4566–4573.
https://doi.org/10.1158/1078-0432.CCR-21-0263
Published: 15 August 2021
View article titled, A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non–small Cell Lung Cancer
Open the PDF for A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non–small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer

Cristina P. Rodriguez, Qian (Vicky) Wu, Jenna Voutsinas, Jonathan R. Fromm, Xiuyun Jiang, Venu G. Pillarisetty, Sylvia M. Lee, Rafael Santana-Davila, Bernardo Goulart, Christina S. Baik, Laura Q.M. Chow, Keith Eaton, Renato Martins
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (4): 837–845.
https://doi.org/10.1158/1078-0432.CCR-19-2214
Published: 14 February 2020
View article titled, A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer
Open the PDF for A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma

Eduardo Méndez, Cristina P. Rodriguez, Michael C. Kao, Sharat Raju, Ahmed Diab, R. Alex Harbison, Eric Q. Konnick, Ganesh M. Mugundu, Rafael Santana-Davila, Renato Martins, Neal D. Futran, Laura Q.M. Chow
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (12): 2740–2748.
https://doi.org/10.1158/1078-0432.CCR-17-3796
Published: 14 June 2018
View article titled, A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma
Open the PDF for A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors

Anthony W. Tolcher, Mario Sznol, Siwen Hu-Lieskovan, Kyriakos P. Papadopoulos, Amita Patnaik, Drew W. Rasco, Donna Di Gravio, Bo Huang, Dhiraj Gambhire, Ying Chen, Aron D. Thall, Nuzhat Pathan, Emmett V. Schmidt, Laura Q.M. Chow
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (18): 5349–5357.
https://doi.org/10.1158/1078-0432.CCR-17-1243
Published: 14 September 2017
View article titled, Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors
Open the PDF for Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities

Christina S. Baik, Eric H. Rubin, Patrick M. Forde, Janice M. Mehnert, Deborah Collyar, Marcus O. Butler, Erica L. Dixon, Laura Q.M. Chow
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (17): 4992–5002.
https://doi.org/10.1158/1078-0432.CCR-16-3066
Published: 31 August 2017
View article titled, Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities
Open the PDF for Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities in another window
Journal Articles

Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity

Valsamo Anagnostou, Mark Yarchoan, Aaron R. Hansen, Hao Wang, Franco Verde, Elad Sharon, Deborah Collyar, Laura Q.M. Chow, Patrick M. Forde
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (17): 4959–4969.
https://doi.org/10.1158/1078-0432.CCR-16-3065
Published: 31 August 2017
View article titled, Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity
Open the PDF for Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity in another window
Journal Articles

PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer

Jennifer H. Yearley, Christopher Gibson, Ni Yu, Christina Moon, Erin Murphy, Jonathan Juco, Jared Lunceford, Jonathan Cheng, Laura Q.M. Chow, Tanguy Y. Seiwert, Masahisa Handa, Joanne E. Tomassini, Terrill McClanahan
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (12): 3158–3167.
https://doi.org/10.1158/1078-0432.CCR-16-1761
Published: 14 June 2017
View article titled, PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer
Open the PDF for PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer in another window
Includes: Supplementary data
Journal Articles

Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN

Laura Q.M. Chow, Chihiro Morishima, Keith D. Eaton, Christina S. Baik, Bernardo H. Goulart, Leslie N. Anderson, Kristi L. Manjarrez, Gregory N. Dietsch, James Kyle Bryan, Robert M. Hershberg, Mary L. Disis, Renato G. Martins
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (10): 2442–2450.
https://doi.org/10.1158/1078-0432.CCR-16-1934
Published: 14 May 2017
View article titled, Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN
Open the PDF for Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN in another window
Includes: Supplementary data